PHARMAC is seeking feedback on a provisional agreement with Celgene Pty Ltd. In summary, this proposal is, from 1 September 2014, to:

• Fund azacitidine (Vidaza) 100 mg injection for patients with intermediate-2 or high risk myelodysplatic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) or MDS-associated acute myeloid leukaemia (AML); and
• Fund lenalidomide (Revlimid) 10 and 25 mg capsules for relapsed refractory multiple myeloma (MM); and
• Reduce the price and subsidy for thalidomide (Thalomid) 50 mg and 100mg capsules

For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-06-26-azacitidine-lenalidomide-thalidomide/